BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 28478507)

  • 1. MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
    Ko CY; Lin CH; Chuang JY; Chang WC; Hsu TI
    Mol Neurobiol; 2018 Apr; 55(4):3211-3223. PubMed ID: 28478507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suberoylanilide hydroxamic acid represses glioma stem-like cells.
    Hsu CC; Chang WC; Hsu TI; Liu JJ; Yeh SH; Wang JY; Liou JP; Ko CY; Chang KY; Chuang JY
    J Biomed Sci; 2016 Nov; 23(1):81. PubMed ID: 27863490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ANGPTL4 Induces TMZ Resistance of Glioblastoma by Promoting Cancer Stemness Enrichment via the EGFR/AKT/4E-BP1 Cascade.
    Tsai YT; Wu AC; Yang WB; Kao TJ; Chuang JY; Chang WC; Hsu TI
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
    Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
    Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QKI deficiency maintains glioma stem cell stemness by activating the SHH/GLI1 signaling pathway.
    Han B; Wang R; Chen Y; Meng X; Wu P; Li Z; Duan C; Li Q; Li Y; Zhao S; Jiang C; Cai J
    Cell Oncol (Dordr); 2019 Dec; 42(6):801-813. PubMed ID: 31292920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleolin is expressed in patient-derived samples and glioblastoma cells, enabling improved intracellular drug delivery and cytotoxicity.
    Balça-Silva J; do Carmo A; Tão H; Rebelo O; Barbosa M; Moura-Neto V; Sarmento-Ribeiro AB; Lopes MC; Moreira JN
    Exp Cell Res; 2018 Sep; 370(1):68-77. PubMed ID: 29902537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
    Mantwill K; Naumann U; Seznec J; Girbinger V; Lage H; Surowiak P; Beier D; Mittelbronn M; Schlegel J; Holm PS
    J Transl Med; 2013 Sep; 11():216. PubMed ID: 24044901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.
    Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y
    Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
    Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
    Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
    Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells.
    Mazor G; Levin L; Picard D; Ahmadov U; Carén H; Borkhardt A; Reifenberger G; Leprivier G; Remke M; Rotblat B
    Cell Death Dis; 2019 Mar; 10(3):246. PubMed ID: 30867410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of TFEB oligomerization by co-treatment of melatonin with vorinostat promotes the therapeutic sensitivity in glioblastoma and glioma stem cells.
    Sung GJ; Kim SH; Kwak S; Park SH; Song JH; Jung JH; Kim H; Choi KC
    J Pineal Res; 2019 Apr; 66(3):e12556. PubMed ID: 30648757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR/FOXO3a/BIM signaling pathway determines chemosensitivity of BMP4-differentiated glioma stem cells to temozolomide.
    Ciechomska IA; Gielniewski B; Wojtas B; Kaminska B; Mieczkowski J
    Exp Mol Med; 2020 Aug; 52(8):1326-1340. PubMed ID: 32788653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells.
    Shi Y; Zhou W; Cheng L; Chen C; Huang Z; Fang X; Wu Q; He Z; Xu S; Lathia JD; Ping Y; Rich JN; Bian XW; Bao S
    Cell Death Differ; 2017 Jan; 24(1):167-180. PubMed ID: 27740621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
    Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
    Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lucanthone, a Potential PPT1 Inhibitor, Perturbs Stemness, Reduces Tumor Microtube Formation, and Slows the Growth of Temozolomide-Resistant Gliomas In Vivo.
    Radin DP; Shifman S; Outhwaite IR; Sharma A; Bases R; Seeliger MA; Tsirka SE
    J Pharmacol Exp Ther; 2024 Mar; 389(1):51-60. PubMed ID: 38296645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome.
    Binder ZA; Siu IM; Eberhart CG; Ap Rhys C; Bai RY; Staedtke V; Zhang H; Smoll NR; Piantadosi S; Piccirillo SG; Dimeco F; Weingart JD; Vescovi A; Olivi A; Riggins GJ; Gallia GL
    PLoS One; 2013; 8(10):e75945. PubMed ID: 24146797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
    Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
    Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
    Garnier D; Meehan B; Kislinger T; Daniel P; Sinha A; Abdulkarim B; Nakano I; Rak J
    Neuro Oncol; 2018 Jan; 20(2):236-248. PubMed ID: 29016925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.